Sca1(+) mesenchymal stromal cells inhibit graft-versus-host disease in mice after bone marrow transplantation

Int Immunopharmacol. 2015 May;26(1):50-7. doi: 10.1016/j.intimp.2015.03.001. Epub 2015 Mar 13.

Abstract

Mesenchymal stromal cells (MSCs) have therapeutic potential for the prevention and treatment of graft-versus-host disease (GVHD). However, MSCs comprise several subpopulations, which have not been individually assessed for their role in GVHD suppression. In this study, we assessed the immunosuppressive effect of bone-related Sca1(+) MSCs on acute GVHD in a MHC-mismatched mouse model of allogeneic hematopoietic stem cell transplantation (HCT). Our results showed that Sca1(+) MSCs decreased the severity of acute GVHD (aGVHD) and prolonged the survival period of allogeneic HCT recipients. This effect was exerted through lowered T lymphocyte infiltration in target organs and by inhibition of CD80/86 expression on host dendritic cells. Furthermore, the expression of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a negative regulator of T cells, was elevated in the recipient splenocytes. In conclusion, bone-related Sca1(+) MSCs subpopulation suppressed GVHD and could be a novel treatment for acute GVHD.

Keywords: Acute GVHD; Bone marrow transplantation; CTLA-4; Co-stimulatory molecule; Mesenchymal stem cell.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Ataxin-1 / immunology*
  • Bone Marrow Transplantation*
  • Cell Transplantation
  • Female
  • Flow Cytometry
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / prevention & control*
  • Infusions, Intravenous
  • Male
  • Mesenchymal Stem Cells / immunology*
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Real-Time Polymerase Chain Reaction
  • Spleen / cytology
  • Spleen / immunology
  • Survival Analysis

Substances

  • Ataxin-1
  • Atxn1 protein, mouse